ASH 2020 | Trial in Progress: pelcitoclax monotherapy, and in combination with JAK2 inhibition in MF
Naveen Pemmaraju, MD, University of Texas MD Anderson Cancer Center, Houston, TX, outlines the details of an in-progress trial (NCT04354727) of pelcitoclax (APG-1252) as a single agent or in combination with ruxolitinib, a JAK2 inhibitor, in myelofibrosis (MF) patients. APG-1252 is a BCL-2/BCL-xL dual inhibitor. It is theorized that JAK2 mutant cells are dependent on BCL-2/BCL-xL to survive, so the combination of BCL and JAK2 inhibition could overcome resistance to JAK2 inhibitors and augment clinical responses. A standard 3+3 dose-escalation design will be employed to determine safety and efficacy of the monotherapy and treatment combination. APG-1252 plus ruxolitinib treatment will begin once the maximum tolerated dose for APG-1252 single-agent treatment has been determined in part 1 of the trial. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Naveen Pemmaraju, MD, has received research funding or grant support from Samus Therapeutics, Cellectis, Stemline Therapeutics, AbbVie, Plexxikon, LFB Biotechnologies, Novartis, SagerStrong Foundation, Affymetrix and Daiichi Sankyo; has received honoraria from Roche Diagnostics, Celgene, Stemline Therapeutics, DAVA Oncology, AbbVie, Incyte Corporation, Blueprint Medicines, Novaritis and MustangBio; and has done consultancy work for Pacylex Pharmaceuticals.
